Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study

Robert Orenstein, Erik Dubberke, Robert Hardi, Arnab Ray, Kathleen Mullane, Darrell S. Pardi, Mayur S. Ramesh, Erik R. Dubberke, Robert Hardi, Ciaran Kelly, Paul Mariani, Bharat Misra, Kathleen Mullane, Robert Orenstein, Darrell S. Pardi, Connie S. Price, Mayur S. Ramesh, Arnab Ray, DImitri Drekonja

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Background. Managing recurrent Clostridium difficile infection (CDI) presents a significant challenge for clinicians and patients. Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, yet availability of a standardized, safe, and effective product has been lacking. Our aim in this study was to assess the safety and effectiveness of RBX2660 (microbiota suspension), a commercially prepared FMT drug manufactured using standardized processes and available in a ready-to-use format. Methods. Patients with at least 2 recurrent CDI episodes or at least 2 severe episodes resulting in hospitalization were enrolled in a prospective, multicenter open-label study of RBX2660 administered via enema. Intensive surveillance for adverse events (AEs) was conducted daily for 7 days following treatment and then at 30 days, 60 days, 3 months, and 6 months. The primary objective was product-related AEs. A secondary objective was CDI-associated diarrhea resolution at 8 weeks. Results. Of the 40 patients enrolled at 11 centers in the United States between 15 August 2013 and 16 December 2013, 34 received at least 1 dose of RBX2660 and 31 completed 6-month follow-up. Overall efficacy was 87.1% (16 with 1 dose and 11 with 2 doses). Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most common. The frequency and severity of AEs decreased over time. Twenty serious AEs were reported in 7 patients; none were related to RBX2660 or its administration. Conclusions. Among patients with recurrent or severe CDI, administration of RBX2660 via enema appears to be safe and effective.

Original languageEnglish (US)
Pages (from-to)596-602
Number of pages7
JournalClinical Infectious Diseases
Volume62
Issue number5
DOIs
StatePublished - Mar 1 2016

Bibliographical note

Publisher Copyright:
© 2015 The Author 2015.

Keywords

  • Clostridium difficile
  • Fecal microbiota transplant
  • Microbiome
  • Safety

Fingerprint

Dive into the research topics of 'Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study'. Together they form a unique fingerprint.

Cite this